Pre-clinical laboratory evaluation of the new ‘AF’ arterial line filter range

Yarham, Gemma; Mulholland, John
July 2010
Perfusion;Jul2010, Vol. 25 Issue 4, p267
Academic Journal
Introduction: The presence of emboli was recognised relatively early in the history of open heart surgery. The emboli produced during cardiopulmonary bypass have the predisposition to distribute into, and ultimately obstruct, microvessels of all tissues. The Sorin Group has recently developed a new range of arterial line filters. Before the Sorin AF range of filters was released for pre-launch clinical trials, our group performed in vitro laboratory testing of the AF range against a selection of commercially available filters on the global market.Results: The Sorin AF620 and AF640 demonstrate both the smallest prime volume and smallest surface contact area (92ml and 290cm2, respectively).The results of the GME Handling Efficiency experiments ranged by 39.6%, from 95.9% to 56.3%. In terms of an air bolus handling, the results of the Limit Bolus experiment ranged by 97ml, from 147.5ml down to 50ml. The pressure drop across all the filters was measured under steady state experimental conditions. All of the above investigations were considered against surface area and prime volume.Conclusion: It is clear from the results that some commercially available arterial line filters perform better than others, not only in overall performance, but also with regard to individual characteristics. Evaluating arterial line filters for hospital-specific use has to balance pressure drop, surface area, micro air handling, prime volume and gross air handling; all points need to be considered. In the AF620 and AF640, Sorin boast that they are the two smallest prime and smallest surface area filters commercially available on the global market. The Sorin AF filter range performs well in all of the areas we investigated and will be a competitive option for centres, irrespective of which characteristics they use to evaluate and select their arterial line filter.


Related Articles

  • Sorin reports 1st patient in Clepsydra trial.  // Medical Device Daily;12/3/2009, Vol. 13 Issue 232, p7 

    The article announces the enrollment of the first patient in Sorin Group's Clepsydra clinical trial.

  • Product Briefs.  // Medical Device Daily;5/3/2011, Vol. 15 Issue 85, p10 

    The article reports on medical devices, including the new name and industrial design for the LuViva cervical precancer test from Guided Therapeutics, the second clinical trial of the subretinal implant from Retina Implant and the VascuClear Endoscopic Vessel Harvesting (EVH) system from Sorin Group.

  • Perceval S aortic heart valve available in Europe.  // Biomedical Business & Technology;Mar2011, Vol. 34 Issue 3, p15 

    The article reports on the announcement of the commercial availability of the self-anchoring Perceval S aortic heart valve in Europe by Milan, Italy-based Sorin Group in February 2011.

  • Sorin Group reports receiving CE mark for Inspire oxygenators.  // Medical Device Daily;12/7/2011, Vol. 15 Issue 233, p1 

    The article reports on the CE mark received by Sorin Group for Inspire 6, a family of oxygenator systems for cardiopulmonary bypass procedures in adult patients. The system, together with a heart-lung machine, replaces the function of the lungs during cardiac surgery procedures. It is aimed at...

  • Sorin receives CE mark for Paradym RF ICDs and CRT-D.  // Medical Device Daily;5/6/2011, Vol. 15 Issue 88, p1 

    The article reports that a CE mark approval has been given to the Sorin Group for its Paradym RF1 family of implantable cardioverter-defibrillator (ICDs) and cardiac resynchronization therapy for defibrillators (CRT-D). It is noted that these devices automatically adjust for customized therapy...

  • Product Briefs.  // Medical Device Daily;5/2/2011, Vol. 15 Issue 84, p9 

    The article offers information on several medical devices, including the WASPLab specimen processing system from Copan, the Quadrox-1 Neonatal and Pediatric oxygenators and reservoirs from Maquet Cardiovascular and the XTRA autotransfusion device from Sorin Group.

  • An in vitro comparison of the ability of three commonly used pediatric cardiopulmonary bypass circuits to filter gaseous microemboli. Melchior, Richard W.; Rosenthal, Tami; Glatz, Andrew C. // Perfusion;Jul2010, Vol. 25 Issue 4, p255 

    Background: The purpose of this study was to compare the ability of three commonly used pediatric cardiopulmonary bypass (CPB) circuits to filter gaseous microemboli (GME) in an in vitro model. Methods: Devices were tested at different levels of two specific independent variables: volume of air...

  • Sorin opens new international training center.  // Medical Device Daily;1/31/2012, Vol. 16 Issue 20, p6 

    This article reports on the opening of the Advanced Center for Continuous Education on Scientific Solutions (ACCESS) by Sorin Group in Paris, France.

  • Sorin Group launches share buy-back program.  // Medical Device Daily;5/12/2011, Vol. 15 Issue 92, p2 

    The article reports on a share buy-back program launched by Sorin Group.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics